Capivasertib
Truqap · AKT inhibitor
2023 breast-cancer AKT inhibitor; AKI with diarrhea/hyperglycemia.
Antibody-drug conjugate (CD19/PBD)
Zynlonta · LON
Antibody-drug conjugate (CD19/PBD) · approved 2021 · 5 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
CD19-directed pyrrolobenzodiazepine ADC whose capillary-leak-type edema, effusions and fluid overload are the renal-relevant signals in DLBCL.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Edema and effusions (pleural, pericardial, peritoneal) are characteristic PBD-payload toxicities and were common in LOTIS-2; the resulting fluid shifts and AKI are not separately quantified. Tumor lysis is an additional consideration in responding lymphoma.Source: Caimi et al., Lancet Oncol 2021 (LOTIS-2)
Prerenal changes track fluid shifts as edema/effusions accumulate over cycles.
Distilled from: “Edema/effusions accumulate over cycles; prerenal changes track the fluid shifts.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Antibody-drug conjugate of an anti-CD19 antibody linked to a pyrrolobenzodiazepine (PBD) dimer payload. After CD19 binding and internalization, the released PBD cross-links DNA, causing death of malignant B cells in diffuse large B-cell lymphoma.
Vasculature / Endothelium
Glomerular & peritubular capillaries
Class-level context for the major non-renal toxicities of the Antibody-drug conjugate (CD19/PBD) class.
Hematologic
Cytopenias, thrombosis, TMA
Ophthalmic
Keratopathy, uveitis, retinopathy
Pulmonary
Pneumonitis, ILD, effusions, hypertension
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
5 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 410 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
146 of 410 reports
Reported with hospitalization
110 of 410 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Loncastuximab tesirine sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Truqap · AKT inhibitor
2023 breast-cancer AKT inhibitor; AKI with diarrhea/hyperglycemia.
Tecelra · MAGE-A4 TCR-T cell therapy
First TCR-T cell therapy for a solid tumor; CRS-associated hemodynamic AKI.
Komzifti · Menin inhibitor
2025 NPM1-mutated AML menin inhibitor; differentiation syndrome and tumor lysis.
Removab · Trifunctional bispecific (EpCAM×CD3)
Intraperitoneal; cytokine-release- and ascites/paracentesis-driven prerenal AKI; withdrawn (EU) 2017.
Ayvakit · KIT / PDGFRA inhibitor
Edema, intracranial bleeding and cognitive effects.
Vanflyta · FLT3 inhibitor
2023 AML FLT3 inhibitor; tumor lysis and QT.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.